Statera Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Other Revenue	1.49	-	-	-
Revenue	1.49	-	-	-
Cost of Revenue	0.49	-	-	-
Gross Profit	1	-	-	-
Selling, General & Admin	19.11	4.94	2.23	5.37
Research & Development	11.83	5.26	0.59	2.14
Operating Expenses	32.24	10.2	3	7.92
Operating Income	-31.24	-10.2	-3	-7.92
Interest Expense	-1.29	-0.13	-0.12	-0.06
Other Non Operating Income (Expenses)	0.15	-1	-	-0.34
EBT Excluding Unusual Items	-32.38	-11.33	-3.13	-8.32
Merger & Restructuring Charges	-0.8	-0.3	-	-
Impairment of Goodwill	-67.71	-	-	-
Asset Writedown	0.1	-	-	-
Legal Settlements	-2.13	-	-	-
Other Unusual Items	1.03	-0.46	-0.1	2.19
Pretax Income	-101.88	-12.09	-3.22	-6.13
Earnings From Continuing Operations	-101.88	-12.09	-3.22	-6.13
Earnings From Discontinued Operations	0	-	-	-
Net Income to Company	-101.88	-12.09	-3.22	-6.13
Minority Interest in Earnings	0.02	-	-	-
Net Income	-101.85	-12.09	-3.22	-6.13
Net Income to Common	-101.85	-12.09	-3.22	-6.13
Shares Outstanding (Basic)	35	7	20	17
Shares Outstanding (Diluted)	35	7	20	17
Shares Change (YoY)	381.26%	-62.79%	14.67%	-
EPS (Basic)	-2.90	-1.66	-0.16	-0.36
EPS (Diluted)	-2.90	-1.66	-0.16	-0.36
Free Cash Flow	-28.38	-5.09	-0.24	-4.27
Free Cash Flow Per Share	-0.81	-0.70	-0.01	-0.25
Gross Margin	67.16%	-	-	-
Operating Margin	-2100.68%	-	-	-
Profit Margin	-6849.25%	-	-	-
Free Cash Flow Margin	-1908.24%	-	-	-
EBITDA	-30.98	-10.2	-	-
D&A For EBITDA	0.26	0	-	-
EBIT	-31.24	-10.2	-3	-7.92

Updated Nov 14, 2022. Source: S&P Global Market Intelligence. Standard template. Financial Sources.